Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose.


Journal

Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899

Informations de publication

Date de publication:
10 2021
Historique:
received: 30 11 2020
accepted: 20 01 2021
pubmed: 14 2 2021
medline: 23 2 2022
entrez: 13 2 2021
Statut: ppublish

Résumé

The safety of a novel modified-release oral capsule with orlistat and acarbose (MR-OA) was investigated in 67 obese middle-aged White men with a body mass index of 32 to 40 kg/m

Identifiants

pubmed: 33580745
doi: 10.1002/cpdd.920
pmc: PMC8518499
doi:

Substances chimiques

Anti-Obesity Agents 0
Drug Combinations 0
Glycoside Hydrolase Inhibitors 0
Orlistat 95M8R751W8
Acarbose T58MSI464G

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1242-1247

Informations de copyright

© 2021 Empros Pharma AB. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.

Références

Pharm Res. 1998 Feb;15(2):233-8
pubmed: 9523309
J Clin Pharmacol. 1995 Nov;35(11):1103-8
pubmed: 8626884
AAPS J. 2012 Jun;14(2):345-51
pubmed: 22419151
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
Obes Rev. 2020 Dec;21(12):e13127
pubmed: 32869512
Drugs. 2006;66(12):1625-56
pubmed: 16956313
J Nutr. 2002 Jul;132(7):1892-9
pubmed: 12097665
Expert Opin Drug Saf. 2009 Nov;8(6):727-44
pubmed: 19998527
Physiol Rev. 2017 Jan;97(1):411-463
pubmed: 28003328
Clin Drug Investig. 2013 Apr;33(4):263-74
pubmed: 23435929
Arzneimittelforschung. 1989 Oct;39(10):1254-60
pubmed: 2610717
Diabet Med. 2020 Apr;37(4):623-635
pubmed: 31785118
J Pharmacokinet Biopharm. 1977 Aug;5(4):291-334
pubmed: 330836
Obes Sci Pract. 2020 Feb 07;6(3):313-323
pubmed: 32523721
Obes Rev. 2020 Oct;21(10):e13049
pubmed: 32476278
Diabetes Obes Metab. 2016 Jun;18(6):558-70
pubmed: 26936802
Clin Neuropharmacol. 2010 Jul;33(4):181-5
pubmed: 20661024

Auteurs

Stefan Grudén (S)

Empros Pharma AB, Solna, Sweden.

Anders Forslund (A)

Empros Pharma AB, Solna, Sweden.
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.

Göran Alderborn (G)

Empros Pharma AB, Solna, Sweden.
Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Arvid Söderhäll (A)

Empros Pharma AB, Solna, Sweden.

Per M Hellström (PM)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Ulf Holmbäck (U)

Empros Pharma AB, Solna, Sweden.
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH